Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7260889 | 0.76 | PLAU (0.50) | PLAUKMT2AKDM4EMEN1HTT | |
| SCHEMBL10642216 | 0.76 | IDO1 (0.50) | KDM4EHTTSMN1; SMN2TP53TDP1 | |
| SCHEMBL29751039 | 0.76 | PLAU (0.50) | PLAUKMT2AKDM4EMEN1HTT | |
| SCHEMBL30723280 | 0.76 | IDO1 (0.50) | KDM4EHTTSMN1; SMN2TP53TDP1 | |
| SCHEMBL1446736 | 0.76 | PLAU (0.50) | PLAUKMT2AKDM4EMEN1HTT | |
| SCHEMBL13945549 | 0.74 | PLAU (0.48) | PLAUKMT2AKDM4EMEN1HTT | |
| SCHEMBL14250663 | 0.74 | PLAU (0.54) | PLAUKMT2AKDM4EMEN1HTT | |
| SCHEMBL31399738 | 0.74 | PLAU (0.54) | PLAUKMT2AKDM4EMEN1HTT | |
| SCHEMBL2617535 | 0.74 | PLAU (0.34) | PLAUKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL5398756 | 0.73 | PLAU (0.52) | PLAUKMT2AKDM4EMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | claimed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | claimed |
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | UCB Biopharma SRL | 2022-10-25 | — | — | US | disclosed |
| EP-3774741-B1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-08 | — | — | EP | disclosed |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | UCB Biopharma SRL (BE) | 2021-04-01 | — | — | US | disclosed |
| EP-3774741-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-17 | — | — | EP | disclosed |
| CN-111936472-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019192992-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB BIOPHARMA SPRL (BE) | 2019-10-10 | — | — | WO | disclosed |
| US-10301272-B2 | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] | PHENEX PHARMACEUTICALS AG (DE) | 2019-05-28 | — | — | US | disclosed |
| EP-2909205-B1 | 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2909205-B1 | 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| CN-1186322-C | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2005-01-26 | — | — | CN | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20040038239-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| CN-1441779-A | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2003-09-10 | — | — | CN | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1300464-A1 | FUNGAL CELL WALL SYNTHESIS GENE | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | G6PD, DPYD, DHODH | PLAU 1432/4885KMT2A 1415/4885KDM4E 1104/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | PLAU 726/4885KMT2A 2673/4885KDM4E 563/4885 |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | G6PD, DPYD, DHODH | PLAU 1432/4885KMT2A 1415/4885KDM4E 1104/4885 |
| US-20040038239-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | PLAU 3631/4885KMT2A 3421/4885KDM4E 2340/4885 |
| US-10301272-B2 | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] | RORA, RORB, RORC | PLAU 4801/4885KMT2A 996/4885KDM4E 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.